Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Premenopausal Breast Cancer × pembrolizumab × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 146 Triple Negative Breast Neoplasms 142 Carcinoma, Non-Small-Cell Lung 51 Ovarian Neoplasms 38 Melanoma 38 Colorectal Neoplasms 36 Carcinoma, Renal Cell 31 Squamous Cell Carcinoma of Head and Neck 30 Pancreatic Neoplasms 27 Stomach Neoplasms 24 Neoplasm Metastasis 24 Neoplasms 22 Uterine Cervical Neoplasms 21 Endometrial Neoplasms 21 Head and Neck Neoplasms 18 Esophageal Neoplasms 17 Lung Neoplasms 16 Urinary Bladder Neoplasms 14 Carcinoma, Transitional Cell 14 Carcinoma, Hepatocellular 14 Prostatic Neoplasms 12 Small Cell Lung Carcinoma 11 Parkinson Disease 4, Autosomal Dominant Lewy Body 11 Sarcoma 9 Mesothelioma 9 Carcinoma, Ovarian Epithelial 9 Kidney Neoplasms 8 Carcinoma, Merkel Cell 8 Lymphoma 7 Fallopian Tube Neoplasms 7

Interventions

Leuprolide 2 pembrolizumab 1 exemestane 1 Tamoxifen 1 Surgical Procedures, Operative 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02990845 2023-02-22

PEER

National Taiwan University Hospital

Phase 1/2 Terminated

Premenopausal Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡